TrialBMC cancer2023

Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial.

Safa Najafi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.